NCT04779645View on ClinicalTrials.gov

Effects of GRA in Patients With Type 1

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2021

Primary Completion Date

July 17, 2024

Study Completion Date

December 31, 2025

Conditions
Type 1 Diabetes
Interventions
DRUG

REMD-477

12-Week, once weekly subcutaneous injection with 70mg REMD-477

DRUG

Placebo

12-Week, once weekly subcutaneous injection with placebo

Trial Locations (1)

92037

UC San Diego Altman Clinical & Translational Research Institute, La Jolla

All Listed Sponsors
collaborator

REMD Biotherapeutics, Inc.

INDUSTRY

lead

University of California, San Diego

OTHER